The effects of cinnarizine on menopausal symptoms in women.

To evaluate the effectiveness and safety of cinnarizine in the treatment of menopausal symptoms. A total of 100 climacteric and symptomatic women participated in a double-blind, placebo-controlled study. They were divided into two groups of the same size: Gcin, intake of 25 mg of cinnarizine every 12 h for 6 months (n=50); and Gpla, placebo intake every 12 hours for 6 months (n=50). Menopausal symptoms were evaluated according to the Kupperman menopausal index on the first visit and at 6 months of treatment. A total of 62 women completed the study: 27 from the Gcin group and 35 from the Gpla group. Based on the Kupperman menopausal index, there were no statistically significant differences between the two groups before and after the treatment. Our data suggest cinnarizine is not effective on menopausal symptoms because it had no more efficacy than placebo.